Skip to Main Content

The most powerful cholesterol drugs ever invented have become a pharmaceutical cautionary tale, failing to reach their commercial potential because of high sticker prices and an inconvenient need for needles. Esperion Therapeutics (ESPR), a small Michigan company with a pair of approved cholesterol treatments, believes it can replicate their effects in pill form, creating a cheaper, easier-to-take medicine that can succeed where its predecessors faltered.

Esperion said Wednesday that it has bought the rights to an oral treatment that targets PCSK9, a protein found in the liver that regulates LDL “bad” cholesterol. The deal, involving a privately held firm called Serometrix, involves a $12.5 million in upfront cash followed by undisclosed future payments tied to development milestones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.